Table 2 LCH localizations and stratification (SS vs. MS disease) observed during the 27 episodes of disease reactivation/worsening observed in 17 patients and associated with the treatments used during the study

SS LCH, n (%)

11 (41%)

  Bone

11

MS LCH, n (%)

16 (59%)

  Bone, DI and AHD, CNS

2

  Bone, skin, oral mucosa, and DI

1

  Bone, skin, vulvar mucosa

2

  Bone, skin, lymph nodes

1

  Lung and bone

2

  Lung, bone, and DI

1

  Lung, bone, liver, skin, oral mucosa, DI and AHD

1

  Lung, liver

1

  Lung, lymph nodes,

1

  Lung, skin, DI

2

  Skin, anal mucosa, liver

1

  Skin, oral and anal mucosa, liver, hematologic involvement, spleen

1

  No treatment

3

  Bone surgery

1

  AINS

1

  Vinblastine (and steroids)

13

  Cladribine

3

  Cladribine/MTX

1

  Cladribine/bisphosphonates

1

  VP16/aracytine

1

  Steroids

1

  IFN alpha ^a

1

  Liver transplantation

1